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Coronaviruses are prone to emergence into new host species most recently evidenced 
by SARS-CoV-2, the causative agent of the COVID-19 pandemic1. Small animal models 
that recapitulate SARS-CoV-2 disease are desperately needed to rapidly evaluate 
medical countermeasures (MCMs)2,3. SARS-CoV-2 cannot infect wildtype laboratory 
mice due to inefficient interactions between the viral spike (S) protein and the murine 
ortholog of the human receptor, ACE24. We used reverse genetics5 to remodel the 
interaction between S and mACE2 resulting in a recombinant virus (SARS-CoV-2 MA) 
that could utilize mACE2 for entry. SARS-CoV-2 MA replicated in both the upper and 
lower airways of both young adult and aged BALB/c mice. Importantly, disease was 
more severe in aged mice, and showed more clinically relevant phenotypes than those 
seen in HFH4-hACE2 transgenic mice. We then demonstrated the utility of this model 
through vaccine challenge studies in immune competent mice with native expression 
of mACE2. Lastly, we show that clinical candidate interferon (IFN) lambda-1a can 
potently inhibit SARS-CoV-2 replication in primary human airway epithelial cells 
in vitro, and both prophylactic and therapeutic administration diminished replication 
in mice. Our mouse-adapted SARS-CoV-2 model demonstrates age-related disease 
pathogenesis and supports the clinical use of pegylated IFN lambda-1a treatment in 
human COVID-19 infections6.
Zoonotic coronaviruses readily traffic into new host species, as evi-
denced by the emergence of SARS-CoV in 2002-2003, Middle East 
Respiratory Coronavirus in 2012 and SARS-CoV-2, the causative agent 
of the COVID-19 pandemic. SARS-CoV-2 has caused millions of infec-
tions and hundreds of thousands of deaths worldwide. As there are 
currently no approved vaccines and only one antiviral approved for 
emergency use for SARS-CoV-27 small animal model systems are vital 
to better understand COVID-19 disease mechanisms and to evaluate 
medical counter measures (MCMs) for improved global health. Mouse 
models not only provide key insights into the pathogenic mechanisms 
of CoV disease but can serve as high-throughput preclinical evalua-
tion platforms to identify high performance antivirals and vaccines2,8. 
SARS-CoV-2 enters host cells through the binding of the cellular recep-
tor angiotensin-converting enzyme 2 (ACE2). Unfortunately, stand-
ard laboratory mice do not support infection with SARS-CoV-2 due to 
incompatibility of the S protein to the murine ortholog (mACE2) of the 
human receptor, complicating model development4.
Infection of HFH4-hACE2 transgenic mice
Animal models are critical for development of MCMs to combat the 
COVID-19 pandemic. While laboratory mice infected with mouse 
adapted strains of SARS-CoV-1 and MERS-CoV have informed our 
understanding of viral pathogenesis and intervention strategiesSeveral 
animal models for SARS-CoV-2 have been reported with varying degrees 
of viral replication and clinical disease including hACE2 transgenic 
mice9–11, virally transduced hACE2 mice8,12,13, ferrets14, hamsters15,16, and 
non-human primates17–19. To determine the utility of our previously 
characterized HFH4 (FoxJ1) promoter driven hACE2-overexpressing 
transgenic mice as a model for SARS-CoV-2 disease, we infected with 
HFH4-hACE2 mice with SARS-CoV-29,20,21. The HFH4 promoter drives 
expression of hACE2 in ciliated cells of respiratory tract epithelium 
but also in in the central nervous system22,23. HFH4-hACE2 mice infected 
with SARS-CoV-2 lost minimal weight yet only 60% survived by 5 days 
post infection (dpi) (Extended Data 1A-B). Virus was detected in the 
lung on 2 and 5dpi (Extended Data 1C). Similar to previously reported 
SARS-CoV-1 and SARS-CoV-2 infection of HFH4-hACE2 mice, SARS-CoV-2 
virus was detected in the brains of mice that succumbed to infection 
suggesting that mortality was driven by viral neuroinvasion (Extended 
Data 1D)9,21. Lastly, we utilized whole body plethysmography (WBP) to 
monitor pulmonary function in SARS-CoV-2 infected mice24. Using WBP, 
we evaluated several complementary metrics of pulmonary obstruction 
and bronchoconstriction including PenH and Rpef which remained at 
normal levels for the duration of these studies proving further evidence 
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that respiratory infection was likely not a major driver of mortality 
(Extended Data 1F-G). While hACE2 expression driven by the HFH4 
promoter facilitates SARS-CoV-2 infection of mice, the pathogenesis 
observed fails to accurately model the more severe disease manifesta-
tions observed in humans.
Remodeling the SARS-CoV-2 mACE2 binding interface
Rather than genetically alter the host, we next sought to remodel the 
SARS-CoV-2 spike receptor binding domain to facilitate efficient bind-
ing to mACE2. We compared the ACE2 contact residues in the RBDs of 
several group 2B coronaviruses capable of infecting mice to those of 
SARS-CoV-2 (Figure 1A, Extended Data 2)21,25,26. While there is variation 
among SARS-CoV-1, WIV1, and SHC014 at a few amino acid positions, 
residue 498 of SARS-CoV-2 was uniquely divergent, suggesting incom-
patibility of SARS-CoV-2 Q498 with mACE2. In addition, molecular 
modeling of the SARS-CoV-2 RBD and receptor interface predicted a 
loss of interaction between Q498 of the SARS-CoV-2 spike and Q42 of 
hACE2 compared to mACE2 (Figure 1B-C), which may diminish bind-
ing efficiency. Thus, substitution of residue Q498, and adjacent P499, 
with Y and T, respectively, from WIV1 and SARS-CoV-1 might restore 
the interaction with Q42 of mACE2, while preserving interaction with 
hACE2 (Figure 1D-E). Using reverse genetics22, we engineered Q498Y/
P499T into the SARS-CoV-2 S gene and recovered the recombinant virus 
(SARS-CoV-2 MA). Importantly, SARS-CoV-2 MA replicated to slightly 
lower titers compared to parental wildtype (WT) virus in Vero E6 cells 
(Figure 1F) and human primary differentiated bronchiolar airway epi-
thelial cells (HAE) (Figure 1G). Notably, unlike WT virus, SARS-CoV-2 
MA RNA could be detected in cells expressing mACE2 by 24 hours post 
infection (Figure 1H).
Mouse adapted SARS-CoV-2 replicates in the upper and 
lower airways of WT mice
After demonstrating SARS-CoV-2 MA could utilize mACE2 for entry, we 
sought to determine if this virus could infect young adult WT mice. While 
overt clinical signs of infection such as weight loss were not observed in 
young adult BALB/c mice infected with 105 plaque forming units (PFU) 
SARS-CoV-2 MA (Figure 2A), high titer virus replication was noted in 
lung tissue on 2dpi but was cleared by 4dpi (Figure 2B). Under identical 
conditions, SARS-CoV-2 WT replication was not detected. Using WBP to 
monitor pulmonary function as described above, we found SARS-CoV-2 
MA young infected mice showed a small but significant change in PenH 
(Figure 2D) and a significant decrease in Rpef (Figure 2E) on 2dpi, indica-
tive of impaired lung function. Histological analysis of SARS-CoV-2 
MA infected mice revealed insterstitial congestion, epithelial damage, 
inflammatory infiltrate, and peribronchiolar lympocytic inflammation 
surrounding airways on 2dpi which were also the main target of virus 
replication as determined by viral antigen staining (Figure 2F). At 4dpi, 
histological analysis showed increased inflammation and hemorrhage in 
the lung (Figure 2G). Concordant with infectious titer data demonstrat-
ing virus clearance by 4dpi, viral antigen was not detected in lung tissues 
sections at this time (Figure 2B, Figure 2G). Similar to that observed in 
humans, SARS-CoV-2 MA virus was also observed in the upper airway and 
antigen was present in nasal turbinate epithelium on 2dpi (Figure 2C, 
2H). Thus, like often seen in humans, infection of young adult mice with 
SARS-CoV-2 MA resulted in efficient virus replication in the upper and 
lower airways, limited replication in the parenchyma and was associated 
with mild to moderate disease.
Modeling age-related exacerbation of SARS-CoV-2 
disease in mice
Higher morbidity and mortality rates have been consistently observed 
in older human populations throughout the COVID-19 pandemic27. 
Additionally, wildtype and mouse adapted SARS-CoV-1 shows strong 
age dependent disease phenotypes in humans and mice, respec-
tively28,29. To determine if infection of aged mice would recapitulate 
the age-related increase in disease severity observed in humans with 
COVID-19, we infected 1-year-old BALB/c mice with SARS-CoV-2 MA. 
In contrast to young adult mice, aged BALB/c mice exhibited a tran-
sient yet significant decrease in body weight by 3-4dpi compared to 
mock infected mice (Figure 3A) (p-values of weights of old versus 
young SARS-CoV-2 MA infected mice on 3 and 4dpi are <0.0001 and 
0.0040, respectively). Similar to young adult mice, aged mice had 
high titer replication in the lung on 2dpi, and but unlike young adult 
mice viral clearence was delayed as evidenced by detectable virus at 
4dpi (Figure 3B). Similarly, replication in the upper airway persisted 
in half of the mice at 4dpi (Figure 3C). The loss of pulmonary function 
was more pronounced in aged animals as evidenced by significant dif-
ferences in PenH and Rpef among mock and SARS-CoV-2 MA infected 
animals (Figure 3D-E) (PenH was statistically higher in SARS-CoV-2 
MA infected old mice on 2dpi compared young mice with p-value of 
0.0457. Rpef was significantly lower in old infected mice on 2 and 4dpi 
with p-values of 0.0264 and 0.0280, respectively). Compared to young 
mice, SARS-CoV-2 MA infected old mice displayed increased epithelial 
damage, peribronchiolar lymphocytic inflammation, hemorrhage, 
and edema in the lung at 2dpi and 4dpi, and viral antigen was found 
in both conducting airway epithelium and interstitium and nasal epi-
thelium, with minimal antigen staining present at 4dpi, concordant 
with detection of viral titer (Figure 3B., Fig 3F-H). Additionally, several 
proinflammatory cytokines were elevated in the lung, but not serum, 
at 2dpi, indicative of a localized cytokine and chemokine response 
(Extended Data 3).
Vectored vaccine and interferon lambda-1a efficacy 
against SARS-CoV-2
As demonstrated with mouse adapted strains of SARS-CoV-125, a rep-
lication competent SARS-CoV-2 MA strain facilitates the elucidation 
of virus and host factors that guide pathogenesis and disease severity 
and importantly, allows for rapid testing of intervention strategies 
in standard laboratory mice. Utilizing a virus replicon particle (VRP) 
system, we vaccinated 10-week-old BALB/c mice against SARS-CoV-2 
spike (S), nucleocapsid (N), and GFP as a control, boosted after 3 weeks, 
and challenged 4 weeks post boost with SARS-CoV-2 MA. Unlike mice 
vaccinated with GFP or N, serum from S vaccinated mice 3 weeks post 
boost potently neutralized SARS-CoV-2 reporter virus expressing nano-
luciferase (nLUC) (Figure 4A). Upon challenge with SARS-CoV-2 MA, 
only those vaccinated with VRP expressing S significantly diminished 
lung and nasal turbinate titer (Figure 4B-C).
Interferon lambda is a type III interferon whose receptors are largely 
limited to epithelial cells, including the lungs30,31. Treatment with inter-
ferons has been employed as pan viral treatment for several viral infec-
tions, including trials for the treatment of SARS-CoV-1 and MERS-CoV 
infections. Pegylated human interferon lambda-1 (peg-IFN-λ1) is Phase 
3-ready for hepatitis delta virus infection and has been proposed to treat 
COVID-19 patients32. We first sought to determine if peg-IFN-λ1 would 
initiate an antiviral response capable of inhibiting productive infection
of primary human airway epithelial (HAE) cell cultures by SARS-CoV-2. 
Pretreatment of HAE with peg-IFN-λ1 provided a potent dose dependent 
reduction in SARS-CoV-2 infectious virus production (Fig 4D).
To determine if the in vitro antiviral effect of peg-IFN-λ1 translates 
to in vivo efficacy, we performed prophylactic and therapeutic effi-
cacy studies in 1-year old BALB/c mice. We subcutaneously adminis-
tered 2µg peg-IFN-λ1 18hr prior or 12hr after infection with 105 PFU 
SARS-CoV-2 MA. Both prophylactic and therapeutic administration of 
peg-IFN-λ1 significantly prevented weight loss at 2 and 3dpi (Figure 4E) 
and diminished SARS-CoV-2 MA replication in the lung measured at 2dpi 














limited by low limits of detection (Figure 4G). Importantly, both pro-
phylactic and therapeutic peg-IFN-λ1 protected mice from pulmonary 
dysfuction as measured by PenH and Rpef (Figure 4H-I). Peg-IFN-λ1 also 
reduced SARS-CoV-2 MA titer in the lung in treated young mice at 2dpi 
(Extended Data 3A-B). When tested in HFH4-hACE2 mice, peg-IFN-λ1 
reduced lung viral titer at 2dpi, but had no effect at 5dpi (Extended 
Data 3C-E), possibly due to decreased potentancy by 5dpi. Altogether, 
these data demonstrate the utility of these models to rapidly evaluate 
vaccine and therapeutic drug efficacy in standard laboratory mice. 
In addition, we show that peg-IFN-λ1 exerts potent antiviral activity 
against SARS-CoV-2 in vitro and can diminish virus replication in vivo 
even when given therapeutically.
Discussion
Structural studies have solved the SARS-CoV and SARS-CoV-2 RBD inter-
action residues that bind hACE233,34. Coupling molecular modeling and 
reverse genetics22, we altered the SARS-CoV-2 receptor binding domain 
(RBD) allowing viral entry via mACE2 and highlight the precision of 
structure-based predictions in virus entry. Unlike parental wildtype 
(WT) virus, the resultant recombinant virus, SARS-CoV-2 MA, used 
mACE2 for infection in vitro. Importantly, recombinant SARS-CoV-2 
MA did not grow more efficiently than WT virus in primary human 
bronchiolar epithelial cells or Vero cells, suggesting that this virus 
is not more fit in human cells. SARS-CoV-2 MA replicated in both the 
upper and lower airways of BALB/c mice, with more severe disease in 
aged mice, reproducing the age-related increase in disease observed 
in humans. SARS-CoV-2 MA infection is cleared by 4dpi in young, but 
not old adult mice, likely due to control by interferons and the innate 
immune system12,35 and is exemplified by sensitivity to peg-IFN-λ1.
SARS-CoV-2 is a pandemic pathogen of concern and experiments 
to intentionally alter host range was reviewed for risk potential for 
Potential Pandemic Pathogen Care and Oversight (P3C0) concerns prior 
to start of research. By current US review standards, SARS-CoV-2 MA 
was not considered dual use research of concern, which is limited to a 
subset of pathogens. Prior to the start of studies, appropriate discus-
sion and documentation of proposed experiments and protocols were 
reviewed and approvals obtained by institutional and external review. 
We recommend that SARS-CoV-2 MA and its derivitives be maintained 
in a biosafety level 3 laboratory.
Importantly, we show the utility of the SARS-CoV-2 MA model for 
screening MCMs through vaccine challenge studies and the evaluation 
of a novel clinical candidate, pegylated interferon lambda-1. Peg-IFN-λ1 
is a Phase 3-ready drug in clinical development for hepatitis delta virus 
infection. It has been given to over 3000 patients in the context of 
19 clinical trials as a weekly subcutaneous injection, often for 24-48 
weeks to treat patients with chronic viral hepatitis36,37. For SARS-CoV-2, 
peg-IFN-λ1 is a promising therapeutic for the treatment of COVID-19 
infections6, blocks porcine coronavirus replication in gut cells in vitro38, 
and SARS-CoV-1 replication in human airway cells39. Our data, which 
demonstrates reduction in SARS-CoV-2 infection in primary human 
cells and in mice, support further multiple investigator sponsored 
studies currently underway to evaluate peg-IFN-λ1 for prevention 
and treatment of SARS-CoV-2 infection (Clinicaltrials.gov identifiers: 
NCT04331899, NCT04343976, NCT04344600, NCT04354259).
Although the SARS-CoV-2 MA RBD mutations may attenuate the 
function of select human monoclonal antibodies or vaccines in 
mice, this phenotype was not observed with mouse adapted strains 
of SARS-CoV-140–42 or alter the potent neutralizing activity of two 
human monoclonal antibodies that target the SARS-CoV-2 RBD43. In 
any event, we demonstrate that our previously described HFH4-hACE2 
transgenic mouse model supports efficient SARS-CoV-2 replication 
and pathogenesis in vivo, as well21. Consequently, transgenic models 
offer an alternative replication and disease model that uses wildtype 
SARS-CoV-2, appropriate for evaluating therapeutic antibodies 
and other countermeasures that target RBD epitopes altered in 
SARS-CoV-2 MA.
Similar to SARS-CoV-1 infection, SARS-CoV-2 infection of HFH4-hACE2 
transgenic mice results in a mild bronchiolitis in young mice and about 
40% mortality, the latter phenotype associated with viral invasion of the 
CNS9,21,44. Recently, Bao, et al used a murine ACE2 promoter to drive over-
expression of hACE2 and infected 6- to 11-month-old mice showed mild 
weight loss and pulmonary inflammation. The discrepancy in weight 
loss between the HFH4-hACE2 model presented here and the Bao et al. 
study may be due to differences in age of mice utilized or differences in 
hACE2 expression distribution. Virally delivered hACE2 overexpression 
models have also been reported8,12. While these systems allow for rapid 
studies in commercially available mice, including knockout mice, the 
cellular distribution of hACE2 may not faithfully recapitulate endog-
enously expressed ACE2 and proper SARS-CoV-2 tropism.
We note that a new SARS-CoV-2 young and aged BALB/c mouse model 
that captures multiple aspects of SARS-CoV-2 pathogenesis, provides a 
urgently needed high-throughput in vivo system to evaluate MCMs dur-
ing this devastating pandemic. Since this model uses standard immune 
competent laboratory mice, the accessibility, ease of use, availability 
of reagents, cost, and utility far exceeds that of other hACE2 trans-
genic mice, ferret, hamster, and non-human primate models. While this 
model provides a critically necessary tool in COVID-19 countermeasure 
research, it also provides an important first step in SARS-CoV-2 serial 
adaptation in mice25, potentially selecting for variants that develop 
more severe pathogenic manifestations of acute respiratory distress 
syndrome (ARDS), coagulopathies, and other human disease outcomes. 
In addition, the SARS-CoV-2 MA model can be used to evaluate the role 
of host genetics and antiviral defense genes in viral pathogenesis using 
transgenic and knockout mice. Together, these data describe critical 
new animal models, each appropriate for testing of various medical 
countermeasures.
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Fig. 1 | Generation of mouse adapted SARS-CoV-2 MA. (A) Amino acid (AA) 
table of group 2B spike receptor binding domain (RBD) hACE2 interaction 
residues. AA positions are numbered relative to SARS-CoV-1 (above) and 
SARS-CoV-2 (below). Green residues are contacts as determined by published 
crystal structures. AAs colored by BLOSUM62 conservation score relative to 
SARS-CoV-1 Urbani (red=least conserved; blue=most conserved). SARS-CoV-1 
Urbani, SARS-CoV-1 MA15, WIV1, and SHC014 can utilize mACE2 as a functional 
receptor whereas SARS-CoV-2 cannot. Red box indicates Q498 in SARS-CoV-2 
that is a hACE2 contact for both SARS-CoV-1 and SARS-CoV-2, and is uniquely 
divergent in SARS-CoV-2. (B) SARS-CoV-2 WT RBD and hACE2 interface (PDB: 
6m0j). SARS-CoV-2 Q498 (red) interacts with Q42 (magenta) of hACE2. (C) 
Modelling of SARS-CoV-2 WT RBD and mACE2. SARS-CoV-2 Q498 no longer 
interacts with Q42 of mACE2. (D) Modelling of SARS-CoV-2 Q498Y and P499T 
(orange) substitutions restore interaction with Q42 of mACE2. (E) Modelling of 
SARS-CoV-2 Q498Y/P499T maintains interaction with Q42 of hACE2. (F-G) 
Single step growth curve of SARS-CoV-2 WT and SARS-CoV-2 MA in Vero E6 cells 
(F) and differentiated primary human bronchiolar epithelial cells (HAEs) (G). 
Dotted line represents limit of detection (LOD). Log transformed data analyzed 
by 2-way ANOVA followed by Sidak’s multiple comparisons. (F) ‘*’ denotes 
p=0.0053 (36 hours). (H) Non-permissive DBT-9 cells were transfected to 
express hACE2 or mACE2 and infected with SARS-CoV-2 WT and SARS-CoV-2 
MA. Viral RNA was quantified by qRT-PCR at 24 hours post infection and scaled 
to empty vector transfected cells. Log transformed data analyzed by 2-way 
ANOVA followed by Dunnett’s multiple comparisons. ‘*’ denotes p=0.0322 
(hACE2), <0.0001 (mACE2). (F-H) n=3 techical replicates for each group, 
representative of 2 independent experiments. Error bars represent standard 













Fig. 2 | SARS-CoV-2 MA replicates in young BALB/c mice. 12-week-old female 
BALB/c mice were mock infected (gray), or infected with 105 PFU SARS-CoV-2 
WT (black) or MA (red). Data combined from two independent experiments. 
(A) Percent starting weight. Dotted line represents weight loss criteria for 
humane euthanasia. Data analyzed by mixed effects analysis followed by 
Dunnett’s multiple comparisons. (B-C) Viral lung (B) and nasal turbinate (C) 
titer. 2dpi: n=5 WT, n=10 MA; 4dpi: n=5 WT, n=9 MA. Dotted line represents limit 
of detection (LOD). Undetected samples are plotted at half the LOD. Log 
transformed data analyzed by 2-way ANOVA followed by Sidak’s multiple 
comparisons. ‘ND’=not determined. (B) ‘*’ denotes p=<0.0001. (D-E) Whole 
body plethysmography assessing pulmonary function for PenH (D) and  
Rpef (E). Data analyzed by 2-way ANOVA followed by Dunnett’s multiple 
comparisons. Error bars represent standard error about the mean. (D)  
‘*’ denotes p=0.012 (2dpi), 0.0025 (3dpi), 0.0030 (4dpi), 0.0018 (6dpi). (E)  
‘*’ denotes p=0.0426 (1dpi), 0.0194 (2dpi), 0.0442 (3dpi) (F-H) 200X images  
of lung sections from 2dpi (F) and 4dpi (G) and 100X images of nasal  
turbinates from 2dpi (H). Top: hematoxylin and eosin (H&E). Bottom: 
immunohistochemistry staining (IHC) for SARS-CoV-2 nucleocapsid protein, 














Fig. 3 | SARS-CoV-2 MA replicates in old BALB/c mice with minor disease. 
1-year-old female BALB/c were mock infected (gray), or infected with 105 PFU 
SARS-CoV-2 WT (black) or MA (red). Data combined from two independent 
experiments. (A) Percent starting weight. Dotted line represents weight loss 
criteria for humane euthanasia. Data analyzed by mixed effects analysis 
followed by Dunnett’s multiple comparisons. ‘*’ denotes p=<0.0001 (3dpi), 
0.0305 (4dpi). (B-C) Viral lung (B) and nasal turbinate (C) titer. 2dpi & 4dpi: n=5 
WT, n=10 MA. Dotted line represents limit of detection (LOD). Undetected 
samples are plotted at half the LOD. Log transformed data analyzed by 2-way 
ANOVA followed by Sidak’s multiple comparisons. ‘ND’=not determined (B) 
‘*’ denotes p=<0.0001. (D-E) Whole body plethysmography assessing 
pulmonary function for PenH (D) and Rpef (E). Data analyzed by 2-way ANOVA 
followed by Dunnett’s multiple comparisons. Error bars represent standard 
error about the mean. (D) ‘*’ denotes p=0.0014 (2dpi). (E) ‘*’ denotes p=<0.0001 
(2dpi), 0.0242 (3dpi), 0.0130 (4dpi), 0.0481 (5dpi). (F-H) 200X images of lung 
sections from 2dpi (F) and 4dpi (G) and 100X images of nasal turbinates from 
2dpi (H). Top: hematoxylin and eosin (H&E). Bottom: immunohistochemistry 
staining (IHC) for SARS-CoV-2 nucleocapsid protein, counterstained with 















Fig. 4 | Evaluation of prevention and intervention strategies against 
SARS-CoV-2 MA infection in mice. (A-C) Groups of 10-week-old female BALB/c 
mice were vaccinated with VRPs expressing wildtype spike (S, n=10), 
nucleocapsid (N, n=8), or GFP (n=4). (A) 50% inhibitory concentration (IC50) of 
sera from 3 weeks post boost to neutralize SARS-CoV-2 WT. Dotted line 
represents limit of detection (LOD). Log transformed data analyzed by 1-way 
ANOVA followed by Dunnett’s multiple comparisons. ‘*’ denotes p=0.0003. 
(B-C) Lung (B) and nasal turbinate (C) viral titer on 2dpi. Dotted line represents 
LOD. Undetected samples are plotted at half the LOD. Log transformed data 
analyzed as in (A). (B) ‘*’ denotes p=<0.0001. (C) ‘*’ denotes p=0.0360. (D) 
Human primary airway epithelial cells were pretreated for 24hrs with 
peg-IFN-λ1 followed by infection with SARS-CoV-2 WT. Infectious virus in  
apical washes from 48 hours post infection was titered. Remdesivir (RDV)  
was used as positive control. Data representative of two independent 
experiments in unique human donors. (E-I) 1-year-old female BALB/c mice were 
subcutaneously treated with vehicle or with 2µg peg-IFN-λ1 prophylactically or 
therapeutically and infected with SARS-CoV-2 MA. n=5 per group per 
timepoint. (E) Percent starting weight. Dotted line represents weight loss 
criteria for humane euthanasia. Data analyzed by mixed effects analysis 
followed by Dunnett’s multiple comparisons. (B) ‘*’ denotes p=<0.0001 
(prophylactic, 2dpi), 0.0128 (therapeutic, 2dpi), 0.0042 (prophylactic, 4dpi), 
0.0037 (therapeutic, 4dpi). (F-G) Viral titers in the lung (F) and nasal turbinates 
(G) at 2 and 4dpi. Dotted line represents LOD. Log transformed data analyzed 
by 2-way ANOVA followed by Dunnett’s multiple comparisons. (H-I) Whole 
body plethysmography assessing pulmonary function for PenH (H) and Rpef 
(I). Data analyzed as in (E). All error bars represent standard error about the 
mean. (H) ‘*’ denotes p=0.0083 (prophylactic, 2dpi), 0.0080 (therapeutic, 
2dpi), 0.0029 (prophylactic, 3dpi), 0.0020 (therapeutic, 3dpi), 0.0327 
(therapeutic, 4dpi). (I) ‘*’ denotes p=0.0442 (prophylactic, 1dpi), 0.0033 
(therapeutic, 1dpi), 0.0048 (prophylactic, 2dpi), 0.0118 (therapeutic, 3dpi), 
















The generation of recombinant SARS-CoV-2 MA was approved for use 
under BSL3 conditions by the University of North Carolina at Chapel Hill 
Institutional Review Board (UNC-CH IBC) and by a Potential Pandemic 
Pathogen Care and Oversight committee at the National Institute of 
Allergy and Infectious Diseases (NIAID). All animal work was approved 
by Institutional Animal Care and Use Committee at University of North 
Carolina at Chapel Hill according to guidelines outlined by the Asso-
ciation for the Assessment and Accreditation of Laboratory Animal 
Care and the U.S. Department of Agriculture. All work was performed 
with approved standard operating procedures and safety conditions 
for SARS-CoV-2. Our institutional BSL3 facilities have been designed 
to conform to the safety requirements recommended by Biosafety in 
Microbiological and Biomedical Laboratories (BMBL), the U.S. Depart-
ment of Health and Human Services, the Public Health Service, the 
Centers for Disease Control and Prevention (CDC), and the National 
Institutes of Health (NIH). Laboratory safety plans have been submitted, 
and the facility has been approved for use by the UNC Department of 
Environmental Health and Safety (EHS) and the CDC.
SARS-CoV-2 receptor binding domain and ACE2 analysis and 
modelling
Group 2B coronavirus spike and ACE2 amino acid sequences were 
aligned using Geneious Prime (Version 2020.0.5). Accession num-
bers used: SARS-CoV-1 Urbani (AY278741), WIV1 (KF367457), SHC014 
(KC881005), SARS-CoV-2 (MN985325.1), hACE2 (BAB40370), mACE2 
(NP_081562). Protein similarity scores were calculated using BLO-
SUM62 matrix. Contact residues previously identified by crystal struc-
tures33,34,45. Structure modelling was performed using Modeller (Version 
9.20) and visualized using PyMOL (Version 1.8.6.0).
Viruses, cells, and transfections
All viruses used were derived from an infectious clone of SARS-CoV-2, 
which was designed using similar strategies for SARS-CoV and 
MERS-CoV22,46,47. The Q498Y/P499T substitutions were generated by 
site directed mutagenesis using the following primers: Forward: 5’-ATA 
TGG TTT CTA CAC GAC TAA TGG TGT TGG TTA CCA ACC-3’, Reverse: 
5’-TAG TCG TGT AGA AAC CAT ATG ATT GTA AAG GAA AGT AAC AAT 
TAA AAC CTT C-3’. Viruses were derived following systematic cDNA 
assembly of the infections clone, followed by in vitro transcription and 
electroporation into Vero E6 cells. Virus stocks were passaged once on 
Vero E6 cells and titered via plaque assay. Briefly, virus was serial diluted 
and inoculated onto confluent monolayers of Vero E6 cells, followed 
by agarose overlay. Plaques were visualized on day 2 post infection via 
staining with neutral red dye.
Vero E6 cells were obtained from USAMRIID in 2003 (ATCC CRL-1586) 
and were maintained in Dulbecco’s modified Eagle’s medium (DMEM; 
Gibco),5% Fetal Clone II serum (FCII, Hyclone), and 1X antibiotic/ 
antimycotic (Gibco). DBT-9 were previously clonally derived in our lab 
maintained in DMEM, 10% FCII, and 1X antibiotic/antimycotic. Cells 
were confirmed to be netgative for mycoplasma contamination.
For Vero E6 single step growth curve, cells were infected at a multi-
plicity of infection (MOI) of 0.5 for 1 hour. Inoculum was removed and 
monolayer was washed twice with PBS and replaced with media. For 
HAE growth curve, cells were infected at a multiplicity of infection 
(MOI) of 0.5 for 2 hours. Inoculum was removed and cells were washed 
three times with PBS. At designated timepoints, Vero E6 supernatant 
was removed without replacement or HAEs were washed apically with 
200µL 1X PBS for 10 minutes and stored at -80 °C until titered by plaque 
assay as described above.
For ACE2 receptor usage, non-permissive DBT-9 cells were transfected 
with pcDNA3.1 empty-vector, pcDNA3.1-hACE2, or pcDNA3.1-mACE2 
using lipofectamine 2000 (Invitrogen). At 24 hours post transfection, 
cells were infected at an MOI of 0.5 for 1 hour, removed and washed 
twice with PBS. At 24hrs post infection, media was removed, and total 
cellular RNA was collected via TRIzol (Invitrogen) and extracted using 
Direct-Zol RNA MiniPrep kit (Zymo Research). Viral RNA was quantified 
via qRT-PCR using TaqMan Fast Virus 1-Step Master Mix (Thermo Fisher 
Scientific) on a QuantStudio 3 (Applied Biosystems). SARS-CoV-2 RNA 
was quantified using US Centers of Disease Control and Prevention 
diagnostic N1 assay: Forward: 5’-GAC CCC AAA ATC AGC GAA AT-3’, 
probe: 5’-FAM-AC CCC GCA TTA CGT TTG GTG GAC C-BHQ1-3’, reveres: 
5’-TCT GGT TAC TGC CAG TTG AAT CTG-3’. Host 18S rRNA was used 
as housekeeping control (Invitrogen, product number 4319413E). 
Viral RNA was analyzed using ΔΔCt and fold change over viral RNA in 
empty-vector transfected cells.
In vivo Infections
HFH4-hACE2 overexpressing mice were bred and maintained at Uni-
versity of North Carolina at Chapel Hill. BALB/c mice were obtained 
from Envigo (strain 047). Mice were infected with 105 PFU intranasally 
under ketamine/xylazine anesthesia. Body weight was monitored daily 
and WBP was performed as indicated. Briefly, mice were allowed to 
equilibrate in WBP chambers (DSI Buxco respiratory solutions, DSI 
Inc.) for 30 minutes prior to a 5 minute data acquisition period using 
FinePointe software. At indicated timepoints, a subset of mice were 
euthanized by isoflurane overdose and tissue samples were harvested 
for titer and histopathology analysis. A subset of mice for nasal tur-
binate histopathology were perfused with 10% phosphate buffered 
formalin prior to tissue collection. The right caudal lung lobe was taken 
for titer and stored at -80 °C until homogenized in 1mL PBS and titered 
by plaque assay as described above. The left lung lobe was taken for 
histopathology and were fixed in 10% phosphate buffered formalin for 
7 days before paraffin embedding and sectioning.
Histopathology and antigen staining
Lungs were fixed for 7 days in 10% phosphate buffered formalin, par-
affin embedded, and sectioned at 4µm. Serial sections were stained 
with hematoxylin and eosin, and stained for immunohistochemistry 
for SARS-CoV-2 nucleocapsid using a monoclonal anti-SARS-CoV-1 
nucleocapsid antibody (1:250, NB100-56576, Novus Biologicals) on 
deparaffinized sections on the Ventana Discovery Ultra platform 
(Roche). Photomicrographs were captured on an Olympus BX43 light 
microscope at 200X magnification with a DP27 camera using cellSens 
Entry software.
Vaccination studies
Non-select BSL2 Venezuelan equine encephalitis virus strain 3526 
based replicon particles (VRPs) were generated to express GFP, 
SARS-CoV-2 spike (S), or nucleocapsid (N) as described previously5,48. 
Mice were vaccinated via hind footpad infection with 103 VRP in 10 µL, 
boosted identically at 3 weeks post prime, and bled via submandibu-
lar bleed at 3 weeks to confirm presence of neutralizing antibodies. 
Neutralizing antibody levels were assessed via neutralization assay 
using SARS-CoV-2 WT expressing nanoluciferase (nLUC) in place of 
ORF7a. Briefly, the ORF7a gene of SARS-CoV-2 was removed from the 
molecular clone and nLUC inserted downstream of the ORF7a tran-
scription regulatory sequence. Recombinant viruses encoding nLUC 
(SARS-CoV-2 nLUC) were recovered, titered and serial dilutions of sera 
were incubated with virus for 1 hour at 37 °C, then added to monolayers 
of Vero E6 cells. 48hrs post infection, viral infection was quantified 
using nLUC activity via Nano-Glo Luciferase Assay System (Promega). 
50% inhibitory concentration (IC50) values were calculated from full 
dilution curves.
Mice were challenged 4 weeks post boost with 105 PFU intranasally 
under ketamine/xylazine anesthesia. Body weight was monitored daily. 
On day 2 post infection, mice were euthanized by isoflurane overdose 














Pegylated-IFN-λ1 treatment in vitro and in vivo
Peginterferon Lambda-1a was obtained from Eiger BioPharmaceuticals 
by MTA in GMP prefilled syringes, 0.18 mg/syringe (0.4 mg/mL). Primary 
HAE cell cultures were obtained from the Tissue Procurement and Cell 
Culture Core Laboratory in the Marsico Lung Institute/Cystic Fibro-
sis Research Center at UNC. Human tracheobronchial epithelial cells 
provided by Dr. Scott Randell were obtained from airway specimens 
resected from patients undergoing surgery under University of North 
Carolina Institutional Review Board-approved protocols (#03-1396) 
by the Cystic Fibrosis Center Tissue Culture Core. Primary cells were 
expanded to generate passage 1 cells and passage 2 cells were plated at 
a density of 250,000 cells per well on Transwell-COL (12mm diameter) 
supports (Corning). Human airway epithelium cultures (HAE) were 
generated by differentiation at an air-liquid interface for 6 to 8 weeks 
to form well-differentiated, polarized cultures that resembled in vivo 
pseudostratified mucociliary epithelium49. HAEs were treated with a 
range of peg-IFN-λ1 doses basolaterally for 24hrs prior to infection. 
1µM remdesivir was obtained from Gilead Sciences by MTA and was 
used as a positive control. Cultures were infected at an MOI of 0.5 for 
2 hours. Inoculum was removed and culture was washed three times 
with PBS. At 48hrs post infection, apical washes were taken to measure 
viral replication via plaque assays as described above. This study was 
repeated in two separate human donors.
1-year or 10-week-old BALB/c, or 4- to 7-week old HFH4-hACE2 mice were 
subcutaneously treated with a single 2µg dose of peg-IFN-λ1 prophylacti-
cally at 18hrs prior to infection, therapeutically at 12hrs post infection50, 
or PBS vehicle treated, and infected with 105 PFU of SARS-CoV-2 MA intra-
nasally under ketamine/xylazine anesthesia. 4 to 7-week-old HFH4-hACE2 
mice treated as above and infected with 105 PFU of SARS-CoV-2 MA. Body 
weight was monitored daily. WBP was performed as indicated. On days 
indicated, mice were euthanized by isoflurane overdose and tissue sam-
ples were harvested for titer analysis as described above.
Data analysis and presentation
All data visualize and analyzed in Prism (version 8.4.2). Non-parametric 
tests were performed as described in figure legends. Figures arranged 
in Adobe Illustrator (version 24.1).
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data and Material availability
All relevant data is included in this article. Viral genome sequences 
uploaded to GenBank (SARS-CoV-2 MA: MT844088. SARS-CoV-2 nLuc: 
MT844089). Reagents and resources available upon request to cor-
responding author (rbaric@email.unc.edu) and with material transfer 
agreement. Source data are provided with this paper.
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Extended Data Fig. 1 | SARS-CoV-2 infection in HFH4-hACE2 transgenic 
mice. Male and female HFH4-hACE2 mice were infected with 105 PFU 
SARS-CoV-2 WT. (A) Percent starting weight. Dotted line represents weight loss 
criteria for humane euthanasia. n=2 mock and 5 SARS-CoV-2. (B) Survival. (C-D) 
Lung (C) and brain (D) viral titer. Dotted line represents limit of detection 
(LOD). Undetected samples are plotted at half the LOD. ‘x’ symbol indicates 
mice that succumbed to infection. 2dpi: n=2; 5dpi: n=5. (E-F) Whole body 













Extended Data Fig. 2 | Group 2B coronavirus spike receptor binding domain alignment. Amino acid positions are numbered above in reference to SARS-CoV-1, 













































































































































































































Extended Data Fig. 3 | Cytokine analysis in SARS-CoV-2 MA infected 
1-year-old BALB/c mice. Cytokine and chemokine levels in serum and lung 
homogenates of 1-year-old female BALB/c mice from Figures 3 at 2 and 4dpi. For 
each analyte, data analyzed by 2-way ANOVA followed by Sidak’s multiple 
comparisons. ‘*’ denotes p=0.0155 (TNF-α), 0.0189 (IL-6), <0.0001 (MCP-1), 
0.0115 (IL-5), 0.0127 (IL-1α), 0.0004 (G-CSF), 0.0070 (IL-10), 0.0243 (KC), 0.0152 














Extended Data Fig. 4 | Evaluation of peg-IFN-λ1 against SARS-CoV-2 MA 
infection in young BALB/c and HFH4-hACE2 mice. (A-B) 12-week-old female 
BALB/c mice were subcutaneously treated with vehicle or with 2µg peg-IFN-λ1 
prophylactically or therapeutically and infected with SARS-CoV-2 MA. Viral 
titers in the lung (A) and nasal turbinates (B) at 2dpi. n=10 for each group, 
combined from two independent experiments. Dotted line represents limit of 
detection (LOD). Undetected samples plotted at half the LOD. Log transformed 
data analyzed by 1-way ANOVA followed by Holm-Sidak’s multiple comparisons. 
(A) ‘*’ denotes p=<0.0001 (prophylactic), <0.0001 (therapeutic). (C-E) 4- to 
7-week old HFH4-hACE2 male and female mice were treated with peg-IFN-λ1 as 
done in (A-B) and infected with 105 PFU SARS-CoV-2 WT. n=8 vehicle; n=10 
prohpylactic, n=7 therapeutic. (C) Percent starting weight. Dotted line 
represents weight loss criteria for humane euthanasia. Data analyzed by  
mixed effects analysis followed by Sidak’s multiple comparisons. (D) Survival. 
(E) Lung viral titer at 2 and 5dpi. 2dpi: n=4 vehicle, n=4 prophylactic, n=4 
therapeutic: 5dpi: n=3 vehicle, n=4 prophylactic, n=2. Data analyzed by 2-way 
ANOVA followed by Dunnett’s multiple comparisons. ‘*’ denotes p=0.0037 
(prophylactic, 2dpi), 0.0365 (therapeutic, 2dpi). All error bars represent 
standard error about the mean.
